* active sars-cov-2 infection measured by rt-qpcr * has a history of sars, mers infection (self-report, on-site inquiry) * has clinical manifestation of fever (axillary temperature \> 37.0 ℃), dry cough, fatigue, nasal obstruction, runny nose, pharyngeal pain, myalgia, diarrhea, shortness of breath and dyspnea occurred within 14 days before vaccination. * body temperature \> 37.0 ℃ before vaccination * urine pregnancy test positive; * previous severe allergic reactions to vaccination (such as acute allergic reactions, urticaria, dyspnea, angioneurotic edema or abdominal pain) or allergy to known ingredients of inactivated sars-cov-2 vaccine have occurred. * has a history of convulsion, epilepsy, encephalopathy or mental illness or family history. * with congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc. * with severe liver and kidney diseases, uncontrollable hypertension (systolic blood pressure ≥ 140 mmhg, diastolic blood pressure ≥ 90 mmhg), diabetic complications, malignant tumors, various acute diseases, or acute attack period of chronic diseases. * has been diagnosed with congenital or acquired immune deficiency, hiv infection, lymphoma, leukemia, or other autoimmune diseases. * with known or suspected diseases include severe respiratory diseases, severe cardiovascular diseases, liver and kidney diseases, and malignant tumors. * has a history of coagulation dysfunction (e.g. coagulation factor deficiency, coagulation disease) * receiving anti-tb therapy. * patients receiving immunotherapy or inhibitor therapy within 3 months (continuous oral or infusion for more than 14 days) * inoculated live attenuated vaccines within 1 month before this vaccination, other vaccines are inoculated within 14 days before this vaccination. * received blood products within 3 months before this vaccination * received other research drugs within 6 months before this vaccination. * other circumstances judged by investigators that are not suitable for this clinical trial.

* active sars-cov-2 infection measured by rt-qpcr * has a history of sars, mers infection (self-report, on-site inquiry) * has clinical manifestation of fever (axillary temperature \> 37.0 ℃), dry cough, fatigue, nasal obstruction, runny nose, pharyngeal pain, myalgia, diarrhea, shortness of breath and dyspnea occurred within 14 days before vaccination. * body temperature \> 37.0 ℃ before vaccination * urine pregnancy test positive; * previous severe allergic reactions to vaccination (such as acute allergic reactions, urticaria, dyspnea, angioneurotic edema or abdominal pain) or allergy to known ingredients of inactivated sars-cov-2 vaccine have occurred. * has a history of convulsion, epilepsy, encephalopathy or mental illness or family history. * with congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc. * with severe liver and kidney diseases, uncontrollable hypertension (systolic blood pressure ≥ 140 mmhg, diastolic blood pressure ≥ 90 mmhg), diabetic complications, malignant tumors, various acute diseases, or acute attack period of chronic diseases. * has been diagnosed with congenital or acquired immune deficiency, hiv infection, lymphoma, leukemia, or other autoimmune diseases. * with known or suspected diseases include severe respiratory diseases, severe cardiovascular diseases, liver and kidney diseases, and malignant tumors. * has a history of coagulation dysfunction (e.g. coagulation factor deficiency, coagulation disease) * receiving anti-tb therapy. * patients receiving immunotherapy or inhibitor therapy within 3 months (continuous oral or infusion for more than 14 days) * inoculated live attenuated vaccines within 1 month before this vaccination, other vaccines are inoculated within 14 days before this vaccination. * received blood products within 3 months before this vaccination * received other research drugs within 6 months before this vaccination. * other circumstances judged by investigators that are not suitable for this clinical trial.

- active sars-cov-2 infection measured by rt-qpcr - has a history of sars, mers infection (self-report, on-site inquiry) - has clinical manifestation of fever (axillary temperature > 37.0 ℃), dry cough, fatigue, nasal obstruction, runny nose, pharyngeal pain, myalgia, diarrhea, shortness of breath and dyspnea occurred within 14 days before vaccination. - body temperature > 37.0 ℃ before vaccination - urine pregnancy test positive; - previous severe allergic reactions to vaccination (such as acute allergic reactions, urticaria, dyspnea, angioneurotic edema or abdominal pain) or allergy to known ingredients of inactivated sars-cov-2 vaccine have occurred. - has a history of convulsion, epilepsy, encephalopathy or mental illness or family history. - with congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc. - with severe liver and kidney diseases, uncontrollable hypertension (systolic blood pressure ≥ 140 mmhg, diastolic blood pressure ≥ 90 mmhg), diabetic complications, malignant tumors, various acute diseases, or acute attack period of chronic diseases. - has been diagnosed with congenital or acquired immune deficiency, hiv infection, lymphoma, leukemia, or other autoimmune diseases. - with known or suspected diseases include severe respiratory diseases, severe cardiovascular diseases, liver and kidney diseases, and malignant tumors. - has a history of coagulation dysfunction (e.g. coagulation factor deficiency, coagulation disease) - receiving anti-tb therapy. - patients receiving immunotherapy or inhibitor therapy within 3 months (continuous oral or infusion for more than 14 days) - inoculated live attenuated vaccines within 1 month before this vaccination, other vaccines are inoculated within 14 days before this vaccination. - received blood products within 3 months before this vaccination - received other research drugs within 6 months before this vaccination. - other circumstances judged by investigators that are not suitable for this clinical trial.

- active sars-cov-2 infection measured by rt-qpcr - has a history of sars, mers infection (self-report, on-site inquiry) - has clinical manifestation of fever (axillary temperature > 37.0 ℃), dry cough, fatigue, nasal obstruction, runny nose, pharyngeal pain, myalgia, diarrhea, shortness of breath and dyspnea occurred within 14 days before vaccination. - body temperature > 37.0 ℃ before vaccination - urine pregnancy test positive; - previous severe allergic reactions to vaccination (such as acute allergic reactions, urticaria, dyspnea, angioneurotic edema or abdominal pain) or allergy to known ingredients of inactivated sars-cov-2 vaccine have occurred. - has a history of convulsion, epilepsy, encephalopathy or mental illness or family history. - with congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc. - with severe liver and kidney diseases, uncontrollable hypertension (systolic blood pressure ≥ 140 mmhg, diastolic blood pressure ≥ 90 mmhg), diabetic complications, malignant tumors, various acute diseases, or acute attack period of chronic diseases. - has been diagnosed with congenital or acquired immune deficiency, hiv infection, lymphoma, leukemia, or other autoimmune diseases. - with known or suspected diseases include severe respiratory diseases, severe cardiovascular diseases, liver and kidney diseases, and malignant tumors. - has a history of coagulation dysfunction (e.g. coagulation factor deficiency, coagulation disease) - receiving anti-tb therapy. - patients receiving immunotherapy or inhibitor therapy within 3 months (continuous oral or infusion for more than 14 days) - inoculated live attenuated vaccines within 1 month before this vaccination, other vaccines are inoculated within 14 days before this vaccination. - received blood products within 3 months before this vaccination - received other research drugs within 6 months before this vaccination. - other circumstances judged by investigators that are not suitable for this clinical trial.